logo
Nuvation Bio to Present Matching-adjusted Indirect Comparison Data for Taletrectinib vs. Crizotinib During Mini Oral Presentation at the European Lung Cancer Congress 2025

Nuvation Bio to Present Matching-adjusted Indirect Comparison Data for Taletrectinib vs. Crizotinib During Mini Oral Presentation at the European Lung Cancer Congress 2025

NEW YORK--(BUSINESS WIRE)--Mar 25, 2025--
Nuvation Bio Inc. (NYSE: NUVB), a global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today announced that new data from a matching-adjusted indirect comparison study evaluating taletrectinib versus crizotinib in ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC) will be reported in a mini oral presentation at the European Lung Cancer Congress taking place March 26–29, 2025 in Paris, France.
Mini Oral Presentation Overview:
Title: Taletrectinib vs crizotinib in ROS1-positive non-small cell lung cancer: A matching-adjusted indirect comparison
Presenter: Misako Nagasaka, M.D., Ph.D., Associate Professor – Division of Hematology and Oncology, UCI School of Medicine
Date: Thursday, March 27, 2025
Session Time: 4:00 p.m. – 5:05 p.m. CET / 11:00 a.m. – 12:05 p.m. ET
Session: Mini Oral Session 1
Presentation Number: LBA2
The materials will be made available in the Publications section of Nuvation Bio's website after the presentation.
About Taletrectinib
Taletrectinib is an oral, potent, central nervous system-active, selective, next-generation ROS1 inhibitor specifically designed for the treatment of patients with advanced ROS1+ NSCLC. Taletrectinib is being evaluated for the treatment of patients with advanced ROS1+ NSCLC in two Phase 2 single-arm pivotal studies: TRUST-I (NCT04395677) in China, and TRUST-II (NCT04919811), a global study.
Based on pooled results of the TRUST-I and TRUST-II clinical studies, the U.S. FDA has accepted and granted Priority Review to Nuvation Bio's NDA for taletrectinib for advanced ROS1+ NSCLC (line agnostic, full approval) and assigned a PDUFA goal date of June 23, 2025. The U.S. FDA previously granted taletrectinib Breakthrough Therapy Designation for the treatment of patients with locally advanced or metastatic ROS1+ NSCLC who either have or have not previously been treated with ROS1 TKIs, and Orphan Drug Designation for the treatment of patients with ROS1+ NSCLC and other NSCLC indications. In January 2025, China's NMPA approved taletrectinib for the treatment of adult patients with locally advanced or metastatic ROS1+ NSCLC.
About Nuvation Bio
Nuvation Bio is a global biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel product candidates. Nuvation Bio's programs include taletrectinib (ROS1), safusidenib (mIDH1), NUV-1511 (DDC), and NUV-868 (BET). Nuvation Bio was founded in 2018 by biopharma industry veteran David Hung, M.D., who previously founded Medivation, Inc., which brought to patients one of the world's leading prostate cancer medicines. Nuvation Bio has offices in New York, San Francisco, Boston, and Shanghai. For more information, please visit www.nuvationbio.com or follow the Company on LinkedIn and X (@nuvationbioinc).
INDUSTRY KEYWORD: BIOTECHNOLOGY GENERAL HEALTH HEALTH PHARMACEUTICAL ONCOLOGY
SOURCE: Nuvation Bio Inc.
Copyright Business Wire 2025.
PUB: 03/25/2025 08:00 AM/DISC: 03/25/2025 08:00 AM
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Warren Buffett's Berkshire Hathaway Buys Over 5 Million Shares in UnitedHealth Group (UNH)
Warren Buffett's Berkshire Hathaway Buys Over 5 Million Shares in UnitedHealth Group (UNH)

Yahoo

time30 minutes ago

  • Yahoo

Warren Buffett's Berkshire Hathaway Buys Over 5 Million Shares in UnitedHealth Group (UNH)

UnitedHealth Group Incorporated (NYSE:UNH) is one of the most buzzing stocks to invest in right now. CNBC reported on August 14 that Warren Buffett's Berkshire Hathaway bought more than 5 million shares in UnitedHealth Group Incorporated (NYSE:UNH) last quarter, coming up to a stake worth around $1.6 billion. A senior healthcare professional giving advice to a patient in a clinic. UnitedHealth Group Incorporated's (NYSE:UNH) shares soared after Buffett's latest quarterly filing was revealed, marking a 'surprising buy' due to the healthcare company's present reputation. According to VerityData, the stake purchase positions it as the 18th-biggest position in the Berkshire portfolio, standing behind Amazon and Constellation Brands. UnitedHealth Group Incorporated (NYSE:UNH) provides healthcare coverage, data consultancy, and software services. It operates through the OptumRx, OptumInsight, OptumHealth, and UnitedHealthCare segments. While we acknowledge the potential of UNH as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey.

WNS Announces Proxy Advisory Firms ISS and Glass Lewis Recommend Shareholders Vote 'FOR' Proposed Acquisition by Capgemini
WNS Announces Proxy Advisory Firms ISS and Glass Lewis Recommend Shareholders Vote 'FOR' Proposed Acquisition by Capgemini

Business Upturn

time32 minutes ago

  • Business Upturn

WNS Announces Proxy Advisory Firms ISS and Glass Lewis Recommend Shareholders Vote 'FOR' Proposed Acquisition by Capgemini

WNS (Holdings) Limited (NYSE: WNS) ('WNS' or the 'Company'), a digital-led business transformation and services company, today announced that leading independent proxy advisory firms Institutional Shareholder Services Inc. ('ISS') and Glass, Lewis & Co. ('Glass Lewis') have each recommended that shareholders vote 'FOR' the previously announced acquisition of the Company by Capgemini SE (EUR: CAP) ('Capgemini'). The 'FOR' recommendations apply to both proxy voting proposals to be considered at the upcoming Court Meeting and General Meeting of Shareholders ('General Meeting'), each scheduled for August 29, 2025. Business Wire India WNS (Holdings) Limited (NYSE: WNS) ('WNS' or the 'Company'), a digital-led business transformation and services company, today announced that leading independent proxy advisory firms Institutional Shareholder Services Inc. ('ISS') and Glass, Lewis & Co. ('Glass Lewis') have each recommended that shareholders vote 'FOR' the previously announced acquisition of the Company by Capgemini SE (EUR: CAP) ('Capgemini'). The 'FOR' recommendations apply to both proxy voting proposals to be considered at the upcoming Court Meeting and General Meeting of Shareholders ('General Meeting'), each scheduled for August 29, 2025. As previously announced on July 7, 2025, WNS and Capgemini entered into a definitive transaction agreement pursuant to which Capgemini will acquire WNS for a cash consideration of $76.50 per WNS share. The total cash consideration will amount to $3.3 billion, excluding WNS net financial debt. The transaction remains on track to close prior to the end of the calendar year, subject to the satisfaction of customary closing conditions and regulatory approvals. ISS and Glass Lewis have reviewed the proposed transaction and determined that it is in the best interests of WNS shareholders. Both firms cited the Company's evaluation of alternative proposals and implied share price premium as key factors in establishing their 'FOR' recommendations.1 WNS' Board of Directors has also unanimously recommended that shareholders vote 'FOR' this strategic combination at both the upcoming Court Meeting and General Meeting. Shareholders are encouraged to vote as soon as possible. The Company's shareholders are reminded that their vote is extremely important, no matter how many shares they own. Actions to be Taken WNS Shareholders are requested to complete and sign the Forms of Proxy in accordance with the instructions printed thereon and return them to WNS' registered office at 22 Grenville Street, St Helier, Jersey JE4 8PX, Channel Islands (Attn: Mourant Secretaries (Jersey) Limited), so as to be received as soon as possible and in any event not later than 2.00 p.m. (London Time) on August 27, 2025 (in the case of the Court Meeting) or 2.15 p.m. (London Time) on August 27, 2025 (in the case of the General Meeting). WNS Shareholders may also vote online following the instructions set out in the Forms of Proxy, instead of submitting the relevant Forms of Proxy by mail. Votes submitted online must be received not later than 2.00 p.m. (London Time) on August 27, 2025 (in the case of the Court Meeting) or 2.15 p.m. (London Time) on August 27, 2025 (in the case of the General Meeting). It is important that, for the Court Meeting in particular, as many votes as possible are cast so that the Court may be satisfied that there is a fair representation of the opinion of WNS Shareholders. Whether or not you intend to attend and/or vote at the Court Meeting in person, WNS Shareholders are strongly advised to sign and return your Form of Proxy for the Court Meeting (or vote online) as soon as possible and in any event prior to 2.00 p.m. (London Time) on August 27, 2025. Registered Shareholders should follow the voting instructions provided by WNS, as described above, while Beneficial Holders should follow the instructions provided by their broker or other intermediary to ensure their vote is counted. 1Permission to cite ISS and Glass Lewis was neither sought nor obtained. Disclaimer: The above press release comes to you under an arrangement with Business Wire India. Business Upturn take no editorial responsibility for the same. Ahmedabad Plane Crash

Church & Dwight Webcasts Presentation at the 2025 Barclays Global Consumer Staples Conference
Church & Dwight Webcasts Presentation at the 2025 Barclays Global Consumer Staples Conference

Business Wire

timean hour ago

  • Business Wire

Church & Dwight Webcasts Presentation at the 2025 Barclays Global Consumer Staples Conference

EWING, N.J.--(BUSINESS WIRE)--Church & Dwight Co., Inc. (NYSE: CHD) will present at the 2025 Barclays Global Consumer Staples Conference on Wednesday, September 3, 2025 at 1:30 p.m. ET. A link to the broadcast will be provided through the Investors section of Church & Dwight's website. Church & Dwight Co., Inc. (NYSE: CHD) founded in 1846, is the leading U.S. producer of sodium bicarbonate, popularly known as baking soda. The Company manufactures and markets a wide range of personal care, household, and specialty products under recognized brand names such as ARM & HAMMER ®, TROJAN ®, OXICLEAN ®, FIRST RESPONSE ®, NAIR ®, ORAJEL ®, XTRA ®, L'IL CRITTERS ® and VITAFUSION ®, BATISTE ®, WATERPIK ®, ZICAM ®, THERABREATH ®, HERO ® and TOUCHLAND ®. For more information, visit the Company's website.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store